# Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

> **NCT00351858** · PHASE2 · TERMINATED · sponsor: **Neovii Biotech** · enrollment: 40 (estimated)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** ertumaxomab

## Key facts

- **NCT ID:** NCT00351858
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** company focus on other projects
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351858, "Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00351858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*